U.S. Oncology Market Report

To learn more about this report, Download Free Sample Report

U.S. Oncology Market Size

The global U.S. Oncology Market size was valued at USD 93.54 billion in 2025 and is anticipated to reach USD 207.04 billion by 2034, from USD 93.54 billion in 2026, growing at a CAGR of 9.23% during the forecast period from 2026 to 2034.

The oncology therapeutics are governed by multidisciplinary tumor boards and value-based payment models. It is not merely a therapeutic domain but a precision ecosystem integrating molecular pathology, real-world evidence, and adaptive clinical pathways.

MARKET DRIVERS

The demographic inevitability of an aging population, which inherently elevates cancer susceptibility due to accumulated genomic instability and immunosenescence is a major factor propelling the growth of U.S. oncology market. Medicare claims data analyzed by the Centers for Medicare & Medicaid Services reveal that beneficiaries aged 75–84 receive 3.2 times more oncology interventions per capita than those aged 50–64.

The proliferation of biomarker-guided therapies that mandate companion diagnostics as a prerequisite for treatment initiation, thereby expanding the diagnostic-therapeutic cascade is additionally to bolster the growth of U.S. oncology market. The College of American Pathologists’ 2023 Molecular Testing Survey confirms that 91% of accredited U.S. labs now offer next-generation sequencing panels covering at least 50 cancer-associated genes, up from 34% in 2018.

MARKET RESTRAINTS

The unsustainable cost trajectory of novel oncology agents, which triggers payer resistance, access delays, and therapeutic rationing even for clinically validated regimens is restricting the growth of U.S. oncology market. Express Scripts’ Drug Trend Report confirms that oncology accounts for 42% of all specialty drug spend despite representing only 2.1% of total prescriptions.

The acute shortage of medical oncologists and genomic pathologists, which creates geographic and temporal bottlenecks in delivering timely, biomarker-informed care is also hampering the growth of U.S. oncology market. The National Comprehensive Cancer Network’s Access Audit documents that patients in non-metropolitan regions wait an average of 28 days longer for genomic test results and 41 days longer to initiate targeted therapy compared to urban counterparts.

The integration of real-world evidence platforms to dynamically refine treatment pathways by enabling adaptive therapy selection based on longitudinal patient outcomes rather than static clinical trial data is creating new opportunities for the growth of U.S. oncology market. Companies investing in RWE partnerships with community oncology networks can accelerate label expansions, neutralize payer skepticism, and transform post-market surveillance into a clinical decision engine that personalizes therapy in near real time.

MARKET OPPORTUNITIES

The embedding financial navigation and toxicity management directly into care delivery, thereby mitigating non-clinical barriers to treatment adherence is creating new opportunities for the growth of U.S. oncology market. The Oncology Nursing Society’s 2023 Practice Innovation Survey confirms that clinics with embedded financial navigators achieve 22% higher 6-month treatment persistence. Providers who systematize affordability and tolerability as core clinical metrics will capture loyalty and outcomes premium in an increasingly consumer-driven oncology landscape.

MARKET CHALLENGES

The fragmentation of genomic data across siloed platforms, such as hospital EHRs, commercial labs, and payer databases, which impedes longitudinal tracking of biomarker evolution and therapeutic resistance is limiting the growth of U.S. oncology market. This data discontinuity prevents clinicians from detecting emergent resistance mutations or clonal evolution in real time, forcing reactive rather than predictive regimen changes.

The misalignment between value-based payment models and the episodic, high-cost nature of oncology innovation, which disincentivizes adoption of curative-intent therapies with front-loaded expense is also to degrade the growth of U.S. oncology market. The Brookings Institution’s 2023 Payment Reform Analysis notes that current alternative payment models reimburse based on 6-month episode costs, penalizing providers who invest in potentially curative therapies with delayed savings.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Therapy Insights

The targeted therapy segment was the largest and held 58.3% of the U.S. oncology market share in 2025. The Journal of Clinical Oncology’s Practice Patterns Study confirms that oncologists now initiate targeted agents in 83% of metastatic cases where a driver mutation is identified seven when chemotherapy has higher historical response rates due to superior tolerability and progression-free survival.

The immunotherapy segment is likely to grow with a CAGR of 15.1% throughout the forecast period with the FDA approved neoadjuvant nivolumab for resectable NSCLC in 2023 after trials showed 37% improvement in event-free survival. Additionally, the rise of subcutaneous and fixed-dose formulations, such as atezolizumab SC that reduces chair time by 45%, enabling higher patient throughput.

By Indication Insights

The breast cancer segment was the largest by occupying 24.3% of the U.S. oncology market share in 2025 with the molecular heterogeneity enabling sequential lines of targeted therapy. Additionally, 89% of early-stage ER+ patients now receive extended adjuvant endocrine therapy guided by genomic recurrence scores like Oncotype DX, locking in 5–10 years of pharmacotherapy per patient.

The lung cancer segment is lucratively growing with a significant CAGR of 12.7% throughout the forecast period with the integration of early detection via LDCT screening. The NCCN’s 2024 NSCLC Guidelines endorse osimertinib for EGFR-mutated stage IB–IIIA disease after adjuvant trials showed 80% reduction in recurrence.

By Distribution Channel Insights

The hospital pharmacies segment held a dominant share of the U.S. oncology market in 2025. The American Hospital Association’s 2023 Medication Management Survey confirms that 93% of hospitals embed oncology drugs into electronic order sets with auto-substitution protocols for biosimilars, ensuring 85% penetration within 90 days of approval.

The online pharmacies segment is growing lucratively with a CAGR of 18.9% during the forecast period, such as Amazon Pharmacy and Capsule that guarantee next-day delivery of oral oncolytics with nurse hotline support and copay assistance. GoodRx’s 2023 Consumer Behavior Tracker reveals that 41% of patients on kinase inhibitors or hormonal therapies now refill exclusively online, citing price transparency and auto-refill reliability.

KEY MARKET PLAYERS

A few of the major companies in the U.S. oncology market include

• Bristol Myers Squibb
• Merck & Co.
• Novartis
• Amgen
• F. Hoffmann-La Roche
• Regeneron Pharmaceuticals
• Pfizer
• Eli Lilly
• Iovance Biotherapeutics
• OncoSec Medical Incorporated

MARKET SEGMENTATION

This research report on the U.S. oncology market has been segmented based on following categories.

By Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Indication

• Lung
• Stomach
• Colorectal
• Breast
• Prostate
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail
• Online Pharmacies

By Country

• The United States